Syfovre (Pegcetacoplan) for AMD

Overview
Syfovre is approved by the U.S. Food and Drug Administration (FDA) for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Syfovre is also known by its drug name, pegcetacoplan.

Syfovre belongs to a category of drugs called complement inhibitors. It is believed to work by inhibiting the activity of certain proteins in the complement system, which are part of the immune system and contribute to the inflammation and tissue damage seen in AMD.

How do I take it?
Prescribing information states that Syfovre is administered by intravitreal injection (injection into the eye) to each affected eye. The recommended dosing schedule is once every 25 to 60 days. The prescribing doctor will determine the appropriate dosing amount and schedule depending on the recipient’s specific diagnosis.

Side effects
Common side effects of Syfovre include ocular (eye) discomfort, neovascular age-related macular degeneration (a more severe form of AMD with new blood vessel growth), vitreous floaters (small specks or clouds in the field of vision), and conjunctival hemorrhage (bleeding under the conjunctiva of the eye).

Rare but serious side effects may include endophthalmitis (severe eye infection), retinal detachments (separation of the retina from its underlying tissue), retinal vasculitis (inflammation of the blood vessels in the retina), retinal vascular occlusion (blockage of the blood vessels in the retina), intraocular inflammation (inflammation inside the eye), and increased intraocular pressure (pressure inside the eye that can lead to glaucoma).

For more information about this treatment, visit:

Label: Syfovre — Pegcetacoplan Injection, Solution

Syfovre — Drugs.com